5/7/2007 12:13:45 PM
LINTHICUM, Md.--(BUSINESS WIRE)--ANI Pharmaceuticals today announced a major expansion of its Rx capabilities with the acquisition from Solvay Pharmaceuticals, Inc. of two manufacturing facilities located in Baudette, MN. The plants add 173,000 sq. ft. of manufacturing and laboratory capacity, substantially expanding ANI's capabilities and enhancing its already-rapid growth. The facilities, both of which are fully-cGMP qualified, increase ANI's capacity in Rx liquid and solid dose production, including products requiring containment. In addition, the state-of-the-art analytical and stability laboratories increase ANI's research and development capabilities nearly three-fold.
comments powered by